US3941763A
(en)
|
1975-03-28 |
1976-03-02 |
American Home Products Corporation |
PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
|
US4704362A
(en)
|
1977-11-08 |
1987-11-03 |
Genentech, Inc. |
Recombinant cloning vehicle microbial polypeptide expression
|
US4215051A
(en)
|
1979-08-29 |
1980-07-29 |
Standard Oil Company (Indiana) |
Formation, purification and recovery of phthalic anhydride
|
US4456591A
(en)
|
1981-06-25 |
1984-06-26 |
Baxter Travenol Laboratories, Inc. |
Therapeutic method for activating factor VII
|
AU561343B2
(en)
|
1981-10-19 |
1987-05-07 |
Genentech Inc. |
Human immune interferon by recombinant dna
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
US6936694B1
(en)
|
1982-05-06 |
2005-08-30 |
Intermune, Inc. |
Manufacture and expression of large structural genes
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
US4694778A
(en)
|
1984-05-04 |
1987-09-22 |
Anicon, Inc. |
Chemical vapor deposition wafer boat
|
US5189015A
(en)
|
1984-05-30 |
1993-02-23 |
Alfa-Laval Agri International Ab |
Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
|
US5077204A
(en)
|
1984-06-21 |
1991-12-31 |
Chiron Corporation |
Yeast endopeptidase for basic amino-acid site cleavage, preparation and use
|
US4766073A
(en)
|
1985-02-25 |
1988-08-23 |
Zymogenetics Inc. |
Expression of biologically active PDGF analogs in eucaryotic cells
|
US4889919A
(en)
|
1986-08-13 |
1989-12-26 |
Zymogenetics, Inc. |
Biologically active PDGF derived A-chain homodimers
|
DK525384D0
(da)
|
1984-11-05 |
1984-11-05 |
Nordisk Insulinlab |
Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
|
US5157021A
(en)
|
1985-03-15 |
1992-10-20 |
Novo Nordisk A/S |
Insulin derivatives and pharmaceutical preparations containing these derivatives
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
US4868112A
(en)
|
1985-04-12 |
1989-09-19 |
Genetics Institute, Inc. |
Novel procoagulant proteins
|
GR860984B
(en)
|
1985-04-17 |
1986-08-18 |
Zymogenetics Inc |
Expression of factor vii and ix activities in mammalian cells
|
US4745055A
(en)
|
1985-05-07 |
1988-05-17 |
California Biotechnology Inc. |
Fused protein for enzyme immunoassay system
|
KR910006424B1
(ko)
|
1985-08-21 |
1991-08-24 |
인코텍스 비.브이 |
편성브리프(brief) 제조방법
|
US5180583A
(en)
|
1985-11-26 |
1993-01-19 |
Hedner Ulla K E |
Method for the treatment of bleeding disorders
|
WO1987004187A1
(en)
|
1986-01-03 |
1987-07-16 |
Genetics Institute, Inc. |
METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
|
US4786726A
(en)
|
1986-01-06 |
1988-11-22 |
Blood Systems, Inc. |
Factor IX therapeutic blood product, means and methods of preparing same
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
US5543502A
(en)
|
1986-06-24 |
1996-08-06 |
Novo Nordisk A/S |
Process for producing a coagulation active complex of factor VIII fragments
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
EP0832981A1
(en)
|
1987-02-17 |
1998-04-01 |
Pharming B.V. |
DNA sequences to target proteins to the mammary gland for efficient secretion
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
US6060447A
(en)
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
IE69026B1
(en)
|
1987-06-12 |
1996-08-07 |
Immuno Ag |
Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
US5892019A
(en)
|
1987-07-15 |
1999-04-06 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Production of a single-gene-encoded immunoglobulin
|
FR2619314B1
(fr)
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
JP2643968B2
(ja)
|
1988-02-03 |
1997-08-25 |
サントリー株式会社 |
Kex2エンドプロテアーゼ及びその製造方法
|
US5234830A
(en)
|
1988-02-03 |
1993-08-10 |
Suntory Limited |
DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
WO1990005183A1
(en)
|
1988-10-31 |
1990-05-17 |
Immunex Corporation |
Interleukin-4 receptors
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
WO1990009800A1
(en)
|
1989-02-21 |
1990-09-07 |
Washington University |
Modified forms of reproductive hormones
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5766883A
(en)
|
1989-04-29 |
1998-06-16 |
Delta Biotechnology Limited |
Polypeptides
|
SE8901687D0
(sv)
|
1989-05-11 |
1989-05-11 |
Alfa Laval Agri Int |
Fibronectin binding protein as well as its preparation
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
US5194596A
(en)
|
1989-07-27 |
1993-03-16 |
California Biotechnology Inc. |
Production of vascular endothelial cell growth factor
|
US5395760A
(en)
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
DK0417563T3
(da)
|
1989-09-12 |
2000-11-06 |
Hoffmann La Roche |
TNF-bindende proteiner
|
US5935815A
(en)
|
1989-10-25 |
1999-08-10 |
Katholieke Universiteit Leuven |
Process for micro biological production of proteins
|
US5633076A
(en)
|
1989-12-01 |
1997-05-27 |
Pharming Bv |
Method of producing a transgenic bovine or transgenic bovine embryo
|
SE465222C5
(sv)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
US5648273A
(en)
|
1989-12-27 |
1997-07-15 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Hepatic growth factor receptor is the MET proto-oncogene
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
GB9009106D0
(en)
|
1990-04-23 |
1990-06-20 |
3I Res Expl Ltd |
Processes and intermediates for synthetic antibody derivatives
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5453491A
(en)
|
1990-09-11 |
1995-09-26 |
Kiyoshi Takatsu |
Murine interleukin-5 receptor
|
DK0574402T3
(da)
|
1990-11-26 |
1998-05-18 |
Chiron Corp |
Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
ATE145428T1
(de)
|
1990-12-14 |
1996-12-15 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
SG89295A1
(en)
|
1991-03-15 |
2002-06-18 |
Amgen Inc |
Pegylation of polypeptides
|
US5374617A
(en)
|
1992-05-13 |
1994-12-20 |
Oklahoma Medical Research Foundation |
Treatment of bleeding with modified tissue factor in combination with FVIIa
|
CA2102224A1
(en)
|
1991-04-19 |
1992-10-20 |
Toshio Kitamura |
Human interleukin-3-receptor component
|
WO1992021755A1
(en)
|
1991-05-31 |
1992-12-10 |
Genentech, Inc. |
Treatment of hiv-associated immune thrombocytopenic purpura
|
US5846951A
(en)
|
1991-06-06 |
1998-12-08 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions
|
US5227158A
(en)
|
1991-06-10 |
1993-07-13 |
Genentech, Inc. |
Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
|
US5346991A
(en)
|
1991-06-13 |
1994-09-13 |
Genentech, Inc. |
Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
US5116753A
(en)
|
1991-07-30 |
1992-05-26 |
The Salk Institute For Biological Studies |
Maintenance of pancreatic islets
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
AU676150B2
(en)
|
1992-01-23 |
1997-03-06 |
Merck Patent Gmbh |
Monomeric and dimeric antibody-fragment fusion proteins
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
CA2128862C
(en)
|
1992-02-11 |
2008-05-20 |
Jonathan G. Seidman |
Homogenotization of gene-targeting events
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
US6037452A
(en)
|
1992-04-10 |
2000-03-14 |
Alpha Therapeutic Corporation |
Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
|
WO1993024135A1
(en)
|
1992-05-26 |
1993-12-09 |
Immunex Corporation |
Novel cytokine that binds cd30
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
DK0627924T3
(da)
|
1992-10-02 |
2001-04-30 |
Genetics Inst |
Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator
|
US6277975B1
(en)
|
1992-10-23 |
2001-08-21 |
Genetics Institute, Inc. |
Fusions of P-selectin ligand protein and polynucleotides encoding same
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
DE669986T1
(de)
|
1992-11-13 |
1996-10-10 |
Idec Pharma Corp |
Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
|
US5726147A
(en)
|
1993-06-01 |
1998-03-10 |
The Scripps Research Institute |
Human mutant tissue factor compositions useful as tissue factor antagonists
|
US6518013B1
(en)
|
1993-06-07 |
2003-02-11 |
Trimeris, Inc. |
Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
|
US6479055B1
(en)
|
1993-06-07 |
2002-11-12 |
Trimeris, Inc. |
Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
|
US5464933A
(en)
|
1993-06-07 |
1995-11-07 |
Duke University |
Synthetic peptide inhibitors of HIV transmission
|
US6017536A
(en)
|
1993-06-07 |
2000-01-25 |
Trimeris, Inc. |
Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
|
US5621039A
(en)
|
1993-06-08 |
1997-04-15 |
Hallahan; Terrence W. |
Factor IX- polymeric conjugates
|
US6310180B1
(en)
|
1993-06-21 |
2001-10-30 |
Vanderbilt University |
Method for synthesis of proteins
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US6740734B1
(en)
|
1994-01-14 |
2004-05-25 |
Biovitrum Ab |
Bacterial receptor structures
|
JPH09509054A
(ja)
|
1994-02-01 |
1997-09-16 |
アメリカ合衆国 |
抗体部分および非抗体部分を含む融合タンパク質
|
DE4405426A1
(de)
|
1994-02-21 |
1995-08-24 |
Boehringer Mannheim Gmbh |
Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US6372716B1
(en)
|
1994-04-26 |
2002-04-16 |
Genetics Institute, Inc. |
Formulations for factor IX
|
US5648240A
(en)
|
1994-05-24 |
1997-07-15 |
Texas A&M University |
MHC II analog from Staphylococcus aureus
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
US5596080A
(en)
|
1994-10-03 |
1997-01-21 |
E. I. Du Pont De Nemours And Company |
Crosslinking processes/agents for zein
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5591573A
(en)
|
1995-04-10 |
1997-01-07 |
Alpha Therapeutic Corporation |
Method and system for testing blood samples
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5579277A
(en)
|
1995-05-01 |
1996-11-26 |
Apple Computer, Inc. |
System and method for interleaving memory banks
|
US6184344B1
(en)
|
1995-05-04 |
2001-02-06 |
The Scripps Research Institute |
Synthesis of proteins by native chemical ligation
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
US5811524A
(en)
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
BR9609152A
(pt)
|
1995-06-07 |
1999-05-04 |
Trimeris Inc |
Processo para tratamento de infecção por hiv em um individuo inibição da replicação do hiv e composição farmaceutica aceitavel util para o tratamento de infecção por hiv
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US5840529A
(en)
|
1995-08-02 |
1998-11-24 |
Clinical Research Institute Of Montreal |
Mammalian pro-hormone convertase
|
EP1382679A3
(en)
|
1995-09-08 |
2004-11-10 |
Genentech, Inc. |
Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
US5770700A
(en)
*
|
1996-01-25 |
1998-06-23 |
Genetics Institute, Inc. |
Liquid factor IX formulations
|
CA2198968C
(en)
|
1996-03-04 |
2010-02-09 |
Toyofumi Masuda |
Process for production of secretory kex2 derivatives
|
US6458563B1
(en)
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
CA2258153C
(en)
|
1996-07-03 |
2004-08-17 |
Genentech, Inc. |
Hepatocyte growth factor receptor agonists and uses thereof
|
CA2203745A1
(en)
|
1996-07-26 |
1998-01-26 |
Robert Day |
Pro-protein converting enzyme
|
ES2300113T3
(es)
|
1996-08-02 |
2008-06-01 |
Bristol-Myers Squibb Company |
Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo.
|
US6159462A
(en)
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
ZA977959B
(en)
*
|
1996-10-16 |
1998-03-23 |
Alza Corp |
Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity.
|
IN184589B
(sl)
*
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
US6271349B1
(en)
|
1996-12-23 |
2001-08-07 |
Immunex Corporation |
Receptor activator of NF-κB
|
DE69738841D1
(de)
|
1996-12-23 |
2008-08-28 |
Immunex Corp |
Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
|
TW502011B
(en)
|
1997-02-05 |
2002-09-11 |
Ajinomoto Kk |
Process for producing n-long-chain acyl acidic amino acids or salts thereof
|
ATE455552T1
(de)
|
1997-02-14 |
2010-02-15 |
American Nat Red Cross |
Expression des active human factor ix im brustdrüsengewebe transgener tiere
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
CA2225189C
(en)
|
1997-03-06 |
2010-05-25 |
Queen's University At Kingston |
Canine factor viii gene, protein and methods of use
|
RO120148B1
(ro)
|
1997-03-14 |
2005-09-30 |
Idec Pharmaceuticals Corporation |
Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
|
ES2301198T3
(es)
|
1997-06-12 |
2008-06-16 |
Novartis International Pharmaceutical Ltd. |
Polipeptidos artificiales de anticuerpos.
|
DE69837170T2
(de)
|
1997-06-13 |
2007-11-22 |
Amylin Pharmaceuticals, Inc., San Diego |
Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
|
US6310183B1
(en)
|
1997-09-10 |
2001-10-30 |
Novo Nordisk A/S |
Coagulation factor VIIa composition
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
US6008321A
(en)
|
1998-03-16 |
1999-12-28 |
Pharmacopeia, Inc. |
Universal linker for combinatorial synthesis
|
US6281331B1
(en)
|
1998-03-23 |
2001-08-28 |
Trimeris, Inc. |
Methods and compositions for peptide synthesis
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
EP1082137A4
(en)
|
1998-05-06 |
2004-05-19 |
Univ Temple |
REVERSE OF PERCENTAL RESPONSE BY INTERRUPTING THE MACROPHAGE RECEPTOR FcSg (g) RI
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US6355782B1
(en)
|
1998-07-09 |
2002-03-12 |
Baylor College Of Medicine |
Hypohidrotic ectodermal dyplasia genes and proteins
|
JP2002520053A
(ja)
|
1998-07-15 |
2002-07-09 |
ジェネンテック・インコーポレーテッド |
凝固因子fvii/fviiaに対する向上した親和性を持つ組織因子タンパク質変異体
|
CN1309770A
(zh)
|
1998-07-31 |
2001-08-22 |
华莱士·E·卡罗尔 |
确定抗凝治疗因子的设备和方法
|
CA2341029A1
(en)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
AU1262900A
(en)
|
1998-11-06 |
2000-05-29 |
Novo Nordisk A/S |
Method for the production of fvii
|
US6280994B1
(en)
|
1998-11-25 |
2001-08-28 |
Zymogenetics, Inc. |
Zace 1: a human metalloenzyme
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
DK1141014T3
(da)
|
1999-01-06 |
2005-04-11 |
Genentech Inc |
Insulinlignende vækstfaktor (IGF) i mutantvariant
|
WO2000040612A1
(en)
|
1999-01-06 |
2000-07-13 |
Genentech, Inc. |
Insulin-like growth factor (igf) i mutant variants
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
US6602977B1
(en)
|
1999-04-19 |
2003-08-05 |
Biovitrum Ab |
Receptor structures
|
WO2001001749A2
(en)
|
1999-07-02 |
2001-01-11 |
Genentech, Inc. |
FVIIa ANTAGONISTS
|
US6469136B1
(en)
|
1999-07-07 |
2002-10-22 |
Trimeris, Inc. |
Methods and composition for peptide synthesis
|
JP2001151694A
(ja)
|
1999-09-17 |
2001-06-05 |
Takeda Chem Ind Ltd |
タンパク質粉体の製造法
|
DE19963859A1
(de)
|
1999-12-30 |
2001-07-12 |
Apotech Res & Dev Ltd |
Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
JP2003530838A
(ja)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
DK1278763T3
(da)
|
2000-04-28 |
2007-06-11 |
Inflazyme Pharm Ltd |
3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil
|
AU2002218166A1
(en)
|
2000-09-08 |
2002-03-22 |
Universitat Zurich |
Collections of repeat proteins comprising repeat modules
|
US7138119B2
(en)
|
2000-09-15 |
2006-11-21 |
Progenics Pharmaceuticals, Inc. |
Compositions and methods for inhibition of HIV-1 infection
|
US7615537B2
(en)
|
2000-10-25 |
2009-11-10 |
Genzyme Corporation |
Methods for treating blood coagulation disorders
|
WO2002040544A2
(en)
|
2000-11-14 |
2002-05-23 |
Board Of Regents, University Of Texas Systems |
Mutant human factor ix with an increased resistance to inhibition by heparin
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
US20030203845A1
(en)
|
2001-02-05 |
2003-10-30 |
Knudsen Jens Bjerre |
Combined use of factor VII polypeptides and factor IX polypeptides
|
US7419949B2
(en)
|
2001-07-16 |
2008-09-02 |
Novo Noridsk Healthcare A/G |
Single-dose administration of factor VIIa
|
BR0212035A
(pt)
|
2001-09-04 |
2004-08-03 |
Merck Patent Gmbh |
Fator ix modificado
|
ATE364632T1
(de)
|
2001-10-05 |
2007-07-15 |
Affimed Therapeutics Ag |
Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation
|
FR2831170B1
(fr)
|
2001-10-19 |
2004-03-19 |
Inst Nat Sante Rech Med |
Proteines c modifiees activables directement par la thrombine
|
US20030078180A1
(en)
|
2001-10-24 |
2003-04-24 |
Benchmark Research & Technology, Inc. |
Contaminant-tolerant foaming additive
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR101271635B1
(ko)
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
AU2003209446B2
(en)
|
2002-03-01 |
2008-09-25 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
CN100343393C
(zh)
|
2002-03-15 |
2007-10-17 |
布赖汉姆妇女医院 |
适合治疗剂全身性递送的中央气道给药
|
US7425619B2
(en)
|
2002-08-14 |
2008-09-16 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
US7217798B2
(en)
|
2003-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of Fc-fusion protein serum half-lives by mutagenesis
|
EP1562972B1
(en)
|
2002-10-15 |
2010-09-08 |
Facet Biotech Corporation |
ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
CN102139114A
(zh)
|
2003-02-26 |
2011-08-03 |
尼克塔治疗公司 |
聚合物-因子viii部分缀合物
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US20050281829A1
(en)
|
2003-05-06 |
2005-12-22 |
Hehir Cristina A T |
Fc chimeric proteins with anti-HIV drugs
|
AU2004238263A1
(en)
|
2003-05-06 |
2004-11-25 |
Syntonix Pharmaceuticals, Inc. |
Inhibition of drug binding to serum albumin
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
EP3552627A1
(en)
|
2003-05-06 |
2019-10-16 |
Bioverativ Therapeutics Inc. |
Clotting factor-fc chimeric proteins to treat hemophilia
|
US7212798B1
(en)
|
2003-07-17 |
2007-05-01 |
Cisco Technology, Inc. |
Adaptive AGC in a wireless network receiver
|
JP2005060378A
(ja)
|
2003-07-28 |
2005-03-10 |
Yamanouchi Pharmaceut Co Ltd |
生理活性蛋白質含有凍結乾燥製剤
|
US20050152979A1
(en)
|
2003-09-05 |
2005-07-14 |
Cell Therapeutics, Inc. |
Hydrophobic drug compositions containing reconstitution enhancer
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
AU2004290070A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
US8263084B2
(en)
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
AU2004282984B2
(en)
|
2003-11-13 |
2011-07-14 |
Hanmi Science Co., Ltd. |
Protein complex using immunoglobulin fragment andmethod for the preparation thereof
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
JP2007511604A
(ja)
|
2003-11-18 |
2007-05-10 |
アイコニック セラピューティクス インコーポレイティッド |
キメラタンパク質の均質製剤
|
EP3378470A1
(en)
|
2003-12-19 |
2018-09-26 |
Novo Nordisk Health Care AG |
Stabilised compositions of factor vii polypeptides
|
US20050249723A1
(en)
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
US20080089892A1
(en)
|
2004-01-12 |
2008-04-17 |
Eli Lilly And Co. |
Fc Region Variants
|
BRPI0509117A
(pt)
|
2004-03-04 |
2007-08-28 |
Wyeth Corp |
método de liofilização para melhorar a cristalização de excipientes
|
WO2005092925A2
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
SI2471813T1
(sl)
|
2004-07-15 |
2015-03-31 |
Xencor, Inc. |
Optimirane Fc variante
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
PL1824988T3
(pl)
|
2004-11-12 |
2018-01-31 |
Bayer Healthcare Llc |
Ukierunkowana na miejsce modyfikacja czynnika VIII
|
AU2005307789A1
(en)
|
2004-11-16 |
2006-05-26 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
PL1827483T3
(pl)
|
2004-12-15 |
2014-12-31 |
Swedish Orphan Biovitrum Ab Publ |
Formulacje terapeutyczne czynnika wzrostu keratynocytów
|
US20060162552A1
(en)
|
2005-01-26 |
2006-07-27 |
Mohawk Valley Energy Solutions, Inc. |
Systems and methods for controlling room air quality
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
US7956160B2
(en)
|
2005-07-22 |
2011-06-07 |
Amgen Inc. |
Concentrated protein lyophilates, methods, and uses
|
MX2008001865A
(es)
|
2005-08-12 |
2008-04-15 |
Human Genome Sciences Inc |
Proteinas de fusion de albumina.
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
US7666622B2
(en)
|
2005-10-19 |
2010-02-23 |
Regeneron Pharmaceuticals, Inc. |
Monomeric self-associating fusion polypeptides and therapeutic uses thereof
|
PL1942868T5
(pl)
|
2005-11-01 |
2023-12-27 |
Wyeth Llc |
Roztwór chlorku sodu do odtwarzania lub rozcieńczania leku
|
US8759292B2
(en)
|
2006-02-03 |
2014-06-24 |
Prolor Biotech, Llc |
Long-acting coagulation factors and methods of producing same
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
EP1820508A1
(en)
|
2006-02-21 |
2007-08-22 |
CSL Behring GmbH |
Coagulation factor X polypeptides with modified activation properties
|
AU2007223888A1
(en)
|
2006-03-06 |
2007-09-13 |
Amunix, Inc. |
Genetic packages and uses thereof
|
JP5374359B2
(ja)
|
2006-03-17 |
2013-12-25 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
安定化されたポリペプチド化合物
|
DK2004683T3
(en)
|
2006-03-24 |
2016-08-22 |
Biogen Hemophilia Inc |
PC5 AS A FACTOR IX PROPEPTID PROCESSING ENZYM
|
PL2631242T3
(pl)
|
2006-04-04 |
2023-03-20 |
Takeda Pharmaceutical Company Limited |
Sposób zatężania polipeptydu
|
KR101492422B1
(ko)
|
2006-04-11 |
2015-02-12 |
체에스엘 베링 게엠베하 |
치료용 폴리펩타이드의 생체내 회수율을 증가시키는 방법
|
KR20090013816A
(ko)
|
2006-05-24 |
2009-02-05 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
|
WO2007144173A1
(en)
|
2006-06-14 |
2007-12-21 |
Csl Behring Gmbh |
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
US7939632B2
(en)
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
EP2423305A1
(en)
|
2006-06-19 |
2012-02-29 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IX polypeptides and use thereof for treatment
|
WO2008022151A1
(en)
|
2006-08-15 |
2008-02-21 |
Inspiration Biopharmaceuticals, Inc. |
Prophylactic treatment of hemophilia
|
US8015841B2
(en)
|
2006-09-08 |
2011-09-13 |
Praxair Technology, Inc. |
Cryogenic refrigeration system for lyophilization
|
US20100254944A1
(en)
|
2006-09-14 |
2010-10-07 |
Mani Subramanian |
Albumin Fusion Proteins
|
US7700734B2
(en)
|
2007-01-09 |
2010-04-20 |
Shu-Wha Lin |
Recombinant human factor IX and use thereof
|
US20080260738A1
(en)
|
2007-04-18 |
2008-10-23 |
Moore Margaret D |
Single chain fc, methods of making and methods of treatment
|
EP2369005B1
(en)
|
2007-06-21 |
2013-04-03 |
Technische Universität München |
Biological active proteins having increased in vivo and/or in vitro stability
|
KR20100058541A
(ko)
|
2007-08-15 |
2010-06-03 |
아뮤닉스 인코포레이티드 |
생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
|
US20110154516A1
(en)
|
2007-10-15 |
2011-06-23 |
Stafford Darrel W |
Human factor ix variants with an extended half life
|
WO2009082648A1
(en)
*
|
2007-12-21 |
2009-07-02 |
Inspiration Biopharmaceuticals, Inc. |
Stabilized factor ix formulations containing trehalose
|
NZ598193A
(en)
|
2007-12-27 |
2012-12-21 |
Baxter Int |
Chemically Modified Factor IX
|
TWI538916B
(zh)
|
2008-04-11 |
2016-06-21 |
介控生化科技公司 |
經修飾的因子vii多肽和其用途
|
CA2721362A1
(en)
|
2008-04-16 |
2009-11-19 |
Bayer Healthcare Llc |
Site-directed modification of factor ix
|
CA2721683A1
(en)
|
2008-04-16 |
2009-11-12 |
Bayer Healthcare Llc |
Modified factor ix polypeptides and uses thereof
|
EP2444491B1
(en)
|
2008-04-21 |
2016-11-16 |
Novo Nordisk Healthcare Ag |
Hyperglycosylated human coagulation factor IX
|
MY158228A
(en)
|
2008-04-24 |
2016-09-15 |
Cantab Biopharmaceuticals Patents Ltd |
Factor ix conjugates with extended half-lives
|
CA2729972C
(en)
|
2008-08-05 |
2018-11-20 |
Wyeth Llc |
Lyophilization above collapse
|
JP2012500250A
(ja)
|
2008-08-21 |
2012-01-05 |
オクタファルマ アクチェン ゲゼルシャフト |
組換えにより産生したヒト第viii及び第ix因子
|
CA2737407A1
(en)
*
|
2008-09-24 |
2010-04-01 |
Stabilitech Ltd. |
Method for preserving polypeptides using a sugar and polyethyleneimine
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
ES2730800T3
(es)
|
2009-02-03 |
2019-11-12 |
Amunix Pharmaceuticals Inc |
Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
|
EP3243835B1
(en)
|
2009-02-11 |
2024-04-10 |
Albumedix Ltd |
Albumin variants and conjugates
|
CN102482340B
(zh)
|
2009-04-06 |
2015-05-13 |
诺沃—诺迪斯克有限公司 |
因子viii蛋白向血小板的靶向递送
|
DK2440228T3
(en)
|
2009-06-08 |
2018-12-17 |
Amunix Operating Inc |
Glucose regulating polypeptides and methods for their preparation and use
|
CN106916229A
(zh)
|
2009-06-08 |
2017-07-04 |
阿穆尼克斯运营公司 |
生长激素多肽及其制备和使用方法
|
AU2010263058A1
(en)
|
2009-06-18 |
2012-01-12 |
Wyeth Llc |
Lyophilized formulations for small modular immunopharmaceuticals
|
RU2563231C2
(ru)
|
2009-06-25 |
2015-09-20 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Химерные молекулы фактора vii
|
WO2011017070A1
(en)
|
2009-07-28 |
2011-02-10 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
AU2010290131C1
(en)
|
2009-08-24 |
2015-12-03 |
Amunix Operating Inc. |
Coagulation factor VII compositions and methods of making and using same
|
WO2011028344A2
(en)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Interleukin-1 receptor antagonist compositions and methods of making and using same
|
ES2898683T3
(es)
|
2009-08-27 |
2022-03-08 |
Novo Nordisk As |
Direccionamiento del factor tisular a las plaquetas activadas
|
GB2488077A
(en)
|
2009-10-30 |
2012-08-15 |
Novozymes Biopharma Dk As |
Albumin variants
|
EP2353588B1
(en)
|
2010-01-21 |
2015-04-15 |
Agricultural Technology Research Institute |
A sustained release preparation of factor IX
|
AU2011219612A1
(en)
*
|
2010-02-24 |
2012-09-06 |
Arecor Limited |
Stable compositions of Factor IX
|
AR081066A1
(es)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
EA201291482A1
(ru)
|
2010-07-09 |
2013-10-30 |
Байоджен Айдек Хемофилия Инк. |
Химерные факторы коагуляции
|
CN103140237A
(zh)
|
2010-07-09 |
2013-06-05 |
比奥根艾迪克依蒙菲利亚公司 |
因子ix多肽及其使用方法
|
ES2561878T3
(es)
|
2010-09-30 |
2016-03-01 |
Toyama Chemical Co., Ltd. |
Sal de meglumina de 6-fluoro-3-hidroxi-2-pirazinacarboxamida
|
CA2830660A1
(en)
|
2011-05-05 |
2012-11-08 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
US20140315817A1
(en)
|
2011-11-18 |
2014-10-23 |
Eleven Biotherapeutics, Inc. |
Variant serum albumin with improved half-life and other properties
|
CA2863328A1
(en)
|
2012-01-12 |
2013-07-18 |
Biogen Idec Ma Inc. |
Chimeric factor viii polypeptides and uses thereof
|
TR201816253T4
(tr)
|
2012-01-12 |
2018-11-21 |
Bioverativ Therapeutics Inc |
Faktör VIII terapisi almakta olan bireylerde faktör VIII'e karşı immünojenisiteyi azaltmanın yöntemleri.
|
SI3564260T1
(sl)
|
2012-02-15 |
2023-02-28 |
Bioverativ Therapeutics Inc. |
Sestavki faktorja VIII in postopki njegove izdelave in uporabe
|
EP3693000B1
(en)
|
2012-06-08 |
2022-03-02 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
EA029685B1
(ru)
|
2012-07-11 |
2018-04-30 |
Амуникс Оперэйтинг Инк. |
Комплекс фактора viii с xten и белком фактора фон виллебранда и его применение (варианты)
|
US20150252345A1
(en)
|
2012-09-25 |
2015-09-10 |
Biogen Idec Ma Inc. |
Methods of Using FIX Polypeptides
|
EP3943102A1
(en)
|
2012-10-30 |
2022-01-26 |
Bioverativ Therapeutics Inc. |
Methods of using fviii polypeptide
|
EP3318124A3
(en)
|
2013-02-16 |
2018-05-30 |
Albumedix A/S |
Pharmacokinetic animal model
|
TWI788044B
(zh)
|
2013-03-15 |
2022-12-21 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
TWI629993B
(zh)
|
2013-03-15 |
2018-07-21 |
美商生物化學醫療公司 |
因子viii多肽調配物
|
CN114736305B
(zh)
|
2014-01-10 |
2023-05-05 |
比奥贝拉蒂治疗公司 |
因子viii嵌合蛋白及其用途
|
AU2015236340B2
(en)
*
|
2014-03-24 |
2020-02-06 |
Bioverativ Therapeutics Inc. |
Lyophilized factor IX formulations
|
KR20190091292A
(ko)
|
2016-12-02 |
2019-08-05 |
바이오버라티브 테라퓨틱스 인크. |
응고 인자에 대한 면역 내성 유도 방법
|
IL308416A
(en)
|
2016-12-02 |
2024-01-01 |
Bioverativ Therapeutics Inc |
Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
|